Expert Interviews

Expert perspectives on the utilization of genomic profiling in patients with metastatic castration-sensitive prostate cancer to impact treatment decisions.

Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.

Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.

A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.

Comprehensive discussion on the pharmacologic treatment armamentarium available for patients with chronic graft vs host disease.

Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.

Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.

Kami J. Maddocks, MD, reviews findings from the SHINE trial comparing ibrutinib plus bendamustine/rituximab vs bendamustine/rituximab alone in newly diagnosed mantle cell lymphoma.

Focusing on second-line treatment options for EGFR-mutated advanced NSCLC, panelists review the use of mobocertinib and amivantamab, respectively.

Experts briefly reflect on optimal frontline treatment strategies for a patient who presents with EGFR-mutated advanced non–small cell lung cancer.

Lori Leslie, MD, explains how CAR T-cell therapy fits into follicular lymphoma treatment sequencing, highlighting data from the ZUMA-5 trial.

Andre Goy, MD, and Andrew Ip, MD, give an overview of the approval of CAR T-cell therapy for mantle cell lymphoma treatment.

Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.

At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.

Drs Costa and Fonesca close out their discussion by highlighting the endemic racial disparities in multiple myeloma treatment.

A look at some of the unmet needs in transplant-ineligible multiple myeloma, particularly within the unfit patient population.

Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.

After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.